Változások a nem-kissejtes tüdorák diagnosztikus és terápiás stratégiájában

Translated title of the contribution: Changes in the diagnostic and therapeutic strategies of non-small cell lung cancer

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Major advancements have been made in the clinical management of non-small cell lung cancer (NSCLC) in the past decade. This development involved the introduction of pemetrexed and several targeted therapies (bevacizumab, erlotinib, gefitinib) in the first and second line treatments of NSCLC. Novel maintenance therapeutic strategies for NSCLC (erlotinib) and for non-squamous-NSCLC (pemetrexed, bevacizumab+erlotinib) have also been developed resulting in a significant improvement in patient's survival. These changes have modified registrations of various drugs and require continuous update of guidelines and reimbursement schemes as well. These advantages are based on refinement of differential diagnosis of NSCLC and on the development of molecular predictive markers. Our aim is to summarize the changes in the diagnosis and therapy of NSCLC and to present the altered therapeutic scheme.

Translated title of the contributionChanges in the diagnostic and therapeutic strategies of non-small cell lung cancer
Original languageHungarian
Pages (from-to)137-143
Number of pages7
JournalMagyar onkologia
Volume54
Issue number2
DOIs
Publication statusPublished - Jun 1 2010

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Changes in the diagnostic and therapeutic strategies of non-small cell lung cancer'. Together they form a unique fingerprint.

  • Cite this